Η #λεποδισιράνη είναι ένα μικρό παρεμβαλλόμενο #RNA μακράς διάρκειας που αναστέλλει την ηπατική παραγωγή της απολιποπρωτεΐνης (α), η οπόια αποτελεί νέο παράγοντα καρδιαγγειακού κινδύνου #cvd #apolipoprotein(a) #cardiovascular #health #heart #disease #καρδιαγγειακά #ιατρική #medicine #Lepodisiran

Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) | NEJM Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa...

Lepodisiran, RNA pequeño de interferencia de duración extendida dirigido a la síntesis hepática de lipoproteínas, reduce las concentraciones séricas de lipoproteína(a) entre 60 y 180 d después de su administración #lepodisiran #lipoprotein www.nejm.org/doi/full/10....

If you're not redirected in a few seconds, click here

De nou un #RNA, en aquest cas petit, un #siRNA (petit RNA d’interferència) anomenat #lepodisiran esdevé eficaç per reduir significativament la #lipoproteïna de baixa densitat #Lp(a), una LDL que representa un risc elevat de malaltia del #cor.

Experimental Drug Reduces Deadly Cholesterol by 94% in 2025 Study A single dose of lepodisiran, an experimental drug, reduced lipoprotein(a) levels by 94% in a 2025 clinical trial, offering hope for millions at risk of heart disease.

🚀 Breakthrough in cholesterol treatment! Lepodisiran reduced lipoprotein(a) levels by 93.9% in just 6 months, targeting mRNA to block production. A game-changer for millions at risk of heart disease! 💔 #CardioHealth #Lepodisiran

ACC25: Positive results with Lilly's Lp(a)-lowering drug Eli Lilly's lepodisiran has been shown to reduce Lp(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial.

NEWS: #EliLilly's gene-silencing drug #lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least 6 months with a single injection in a phase 2 trial, reinforcing its credentials as a potential new therapy for #cardiovasculardiseases.

Eli Lilly's Lepodisiran Shows Promise in Reducing Heart Disease Risk Factors Significantly Eli Lilly's lepodisiran has demonstrated an impressive reduction in genetically inherited heart disease risk factor lipoprotein(a) by nearly 94% in clinical trials, offering hope for millions at risk.

Eli Lilly's Lepodisiran Shows Promise in Reducing Heart Disease Risk Factors Significantly #United_States #Indianapolis #Heart_Disease #Eli_Lilly #Lepodisiran